Literature DB >> 17444954

Epitope mapping of series of monoclonal antibodies against the hepatocellular carcinoma-associated antigen HAb18G/CD147.

X-M Ku1, C-G Liao, Y Li, X-M Yang, B Yang, X-Y Yao, L Wang, L-M Kong, P Zhao, Z-N Chen.   

Abstract

The hepatocellular carcinoma-associated antigen HAb18G/CD147, a member of CD147 family, could promote tumour invasion and metastasis via inducing the secretion of matrix metalloproteinases (MMP). Anti-CD147 monoclonal antibodies (MoAb) have exhibited obvious inhibitory effect on MMP induction. However, none of the epitopes of these MoAb has been reported. We previously prepared five MoAb against HAb18G/CD147, named HAb18, 3B3, 1B3, 5A5 and 4D2. To map the epitopes of these MoAb, a series of truncated fragments of extracellular region of HAb18G/CD147 was expressed in Escherichia coli and the MoAb-binding affinity to these fragments was examined with an enzyme-linked immunosorbent assay and Western blot. The residues (39)LTCSLNDSATEV(50), (36)KILLTCS(42) and (22)AAGTVFTTVEDL(33) were determined to be the epitopes of HAb18, 3B3 and 1B3, respectively, which were further proved by a dot-blot analysis with synthesized peptides and bioinformatics epitope prediction. The binding regions of MoAb 5A5 and 4D2 were located at residues E(120)-R(203). Then we constructed and expressed full-length HAb18G/CD147 and truncated HAb18G/CD147 without residues A(22)-V(50) in COS-7 cells. Gelatin zymography and Boyden chamber assay showed that the COS-7 cells expressing truncated HAb18G/CD147 failed to induce MMP production and enhance the cells' invasive potential, compared with the cells expressing full-length HAb18G/CD147. Taken together with the obviously inhibitory effects of HAb18 on the function of full-length HAb18G/CD147, these findings suggest that residues (22)AAGTVFTTVEDLGSKILLTCSLNDSATEV(50) may play a critical role in the functions of HAb18G/CD147 on MMP secretion and tumour invasion. These key residues can be used as potential drug target in cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17444954     DOI: 10.1111/j.1365-3083.2007.01930.x

Source DB:  PubMed          Journal:  Scand J Immunol        ISSN: 0300-9475            Impact factor:   3.487


  23 in total

1.  An epitope-specific novel anti-EMMPRIN polyclonal antibody inhibits tumor progression.

Authors:  Miriam Walter; Elina Simanovich; Vera Brod; Nitza Lahat; Haim Bitterman; Michal A Rahat
Journal:  Oncoimmunology       Date:  2015-08-28       Impact factor: 8.110

2.  A chimeric antibody targeting CD147 inhibits hepatocellular carcinoma cell motility via FAK-PI3K-Akt-Girdin signaling pathway.

Authors:  Yuan Wang; Lin Yuan; Xiang-Min Yang; Ding Wei; Bin Wang; Xiu-Xuan Sun; Fei Feng; Gang Nan; Ye Wang; Zhi-Nan Chen; Huijie Bian
Journal:  Clin Exp Metastasis       Date:  2014-11-26       Impact factor: 5.150

3.  Characterization of basigin isoforms and the inhibitory function of basigin-3 in human hepatocellular carcinoma proliferation and invasion.

Authors:  Cheng-Gong Liao; Ling-Min Kong; Fei Song; Jin-Liang Xing; Long-Xin Wang; Zhi-Jian Sun; Hao Tang; Hui Yao; Yang Zhang; Li Wang; Yu Wang; Xiang-Min Yang; Yu Li; Zhi-Nan Chen
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

4.  The glycosylated IgII extracellular domain of EMMPRIN is implicated in the induction of MMP-2.

Authors:  Adriana Papadimitropoulou; Avgi Mamalaki
Journal:  Mol Cell Biochem       Date:  2013-04-06       Impact factor: 3.396

5.  A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: relevance to multiple sclerosis.

Authors:  Smriti M Agrawal; Claudia Silva; Janet Wang; Jade Pui-Wai Tong; V Wee Yong
Journal:  J Neuroinflammation       Date:  2012-04-05       Impact factor: 8.322

6.  Interferon-α/β and anti-fibroblast growth factor receptor 1 monoclonal antibody suppress hepatic cancer cells in vitro and in vivo.

Authors:  Shigeru Sasaki; Tadao Ishida; Minoru Toyota; Akinobu Ota; Hiromu Suzuki; Akinori Takaoka; Hiroshi Yasui; Hiroyuki Yamamoto; Hideyasu Takagi; Masahiro Maeda; Tsutomu Seito; Masayuki Tsujisaki; Yasuhisa Shinomura; Kohzoh Imai
Journal:  PLoS One       Date:  2011-05-09       Impact factor: 3.240

7.  Epitope mapping of metuximab on CD147 using phage display and molecular docking.

Authors:  Bifang He; Canquan Mao; Beibei Ru; Hesong Han; Peng Zhou; Jian Huang
Journal:  Comput Math Methods Med       Date:  2013-06-03       Impact factor: 2.238

8.  Basigin-2 is the predominant basigin isoform that promotes tumor cell migration and invasion and correlates with poor prognosis in epithelial ovarian cancer.

Authors:  Shu-Hua Zhao; Yu Wang; Li Wen; Zhen-Bo Zhai; Zhen-Hua Ai; Nian-Ling Yao; Li Wang; Wen-Chao Liu; Bi-Liang Chen; Yu Li; Hong Yang
Journal:  J Transl Med       Date:  2013-04-08       Impact factor: 5.531

Review 9.  Immunotherapy for liver tumors: present status and future prospects.

Authors:  Pablo Matar; Laura Alaniz; Viviana Rozados; Jorge B Aquino; Mariana Malvicini; Catalina Atorrasagasti; Manuel Gidekel; Marcelo Silva; O Graciela Scharovsky; Guillermo Mazzolini
Journal:  J Biomed Sci       Date:  2009-03-06       Impact factor: 8.410

10.  Involvement of HAb18G/CD147 in T cell activation and immunological synapse formation.

Authors:  Jinsong Hu; Nana Dang; Hui Yao; Yu Li; Hongxin Zhang; Xiangmin Yang; Jing Xu; Huijie Bian; Jinliang Xing; Ping Zhu; Zhinan Chen
Journal:  J Cell Mol Med       Date:  2010-07-15       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.